Clinical studies have shown that FSD could improve quality of life, reduce edema, improve patients’ New York Heart Association (NYHA) heart functional classification, improve left ventricular ejection fraction (LVEF), and reduce aminoterminal pro-brain natriuretic peptide (NT-proBNP) levels.[12,13] However, there is currently no systematic review regarding its efficacy and safety in the treatment of CHF. Here, NPPB is linked to congestive heart failure.